

FDA OKs Ixempra for advanced breast cancer

22 October 2007

The U.S. Food and Drug Administration has approved Ixempra, a new anti-cancer treatment, for use in patients with metastatic or advanced breast cancer.

"This approval is important because it provides certain patients with a new chemotherapy option in instances where other drugs have failed," said Dr. Douglas Throckmorton, deputy director of the FDA's Center for Drug Evaluation and Research.

Ixempra (ixabepilone) was approved for use in combination with another cancer drug, capecitabine, in patients who no longer respond to two other chemotherapy treatments. The prior treatments included an anthracycline (such as doxorubicin or epirubicin) and a taxane (such as paclitaxel or docetaxel).

Ixempra, which is administered by intravenous infusion, was also approved for use alone in patients who no longer benefit from an anthracycline, a taxane and capecitabine.

The drug is distributed by the Bristol-Meyers Squibb Co. of Princeton, N.J.

Copyright 2007 by United Press International

APA citation: FDA OKs Ixempra for advanced breast cancer (2007, October 22) retrieved 15 September 2022 from <https://medicalxpress.com/news/2007-10-fda-oks-ixempra-advanced-breast.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.